CLSD
Clearside Biomedical Inc
$
0.367
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.385
Open
0.3726
VWAP
0.36
Vol
1.53M
Mkt Cap
28.85M
Low
0.3487
Amount
543.33K
EV/EBITDA(TTM)
--
Total Shares
74.73M
EV
21.04M
EV/OCF(TTM)
--
P/S(TTM)
7.10
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
100.00K
-95.71%
-0.065
-40.91%
288.20K
-5.82%
-0.040
-60%
88.00K
-91.52%
-0.040
-60%
Estimates Revision
The market is revising Upward the revenue expectations for Clearside Biomedical, Inc. (CLSD) for FY2025, with the revenue forecasts being adjusted by 20.93% over the past three months. During the same period, the stock price has changed by -52.88%.
Revenue Estimates for FY2025
Revise Upward
+20.93%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-25.5%
In Past 3 Month
Stock Price
Go Down
-52.88%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast CLSD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLSD is 2.50 USD with a low forecast of 2.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
6 Hold
0 Sell
Hold
Current: 0.367
Low
2.00
Averages
2.50
High
3.00
Current: 0.367
Low
2.00
Averages
2.50
High
3.00
Chardan
Daniil Gataulin
Buy -> Neutral
downgrade
2025-07-18
Reason
Chardan
Daniil Gataulin
Price Target
2025-07-18
downgrade
Buy -> Neutral
Reason
Chardan analyst Daniil Gataulin downgraded Clearside Biomedical to Neutral from Buy without a price target after the company said it will explore strategic alternatives. The firm awaits clarity on Clearside's future plans.
H.C. Wainwright
H.C. Wainwright
Buy -> Neutral
downgrade
2025-07-18
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
2025-07-18
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded Clearside Biomedical to Neutral from Buy without a price target after the company said it is exploring strategic alternatives. No agreement for any strategic transaction has been reached and no timetable has been set for the strategic review process, the analyst tells investors in a research note.
JonesResearch
Buy
to
Hold
downgrade
2025-07-17
Reason
JonesResearch
Price Target
2025-07-17
downgrade
Buy
to
Hold
Reason
JonesResearch downgraded Clearside Biomedical to Hold from Buy without a price target after the company said it is exploring strategic alternatives to maximize shareholder value. The firm finds it unclear if this strategic review will result in a transaction. It cites Clearside's "unclear path ahead" for the downgrade.
Needham
Buy
to
Hold
downgrade
$3
2025-07-17
Reason
Needham
Price Target
$3
2025-07-17
downgrade
Buy
to
Hold
Reason
Needham downgraded Clearside Biomedical to Hold from Buy with a $3 price target.
Needham
Buy -> Hold
downgrade
2025-07-17
Reason
Needham
Price Target
2025-07-17
downgrade
Buy -> Hold
Reason
Needham downgraded Clearside Biomedical to Hold from Buy. The firm sees an uncertain path forward for Clearside after the company hired an investment bank to explore strategic alternatives. The decision is \"disappointing\" since the company has a Phase 3 ready-asset for wet age-related macular degeneration that demonstrated the potential for flexible dosing, the analyst tells investors in a research note. Needham believes Clearside has limited options to secure adequate funding. The stock in midday trading is down 32% to 57c.
Stifel
Buy
to
Hold
downgrade
$8 -> $2
2025-07-17
Reason
Stifel
Price Target
$8 -> $2
2025-07-17
downgrade
Buy
to
Hold
Reason
Stifel downgraded Clearside Biomedical to Hold from Buy with a price target of $2, down from $8. In a challenging financing environment, Clearside has arrived at the end of its cash runway with no new injection of capital and is now considering strategic alternatives, the analyst tells investors in a research note. The firm added that, given the company has been seeking capital influx for some time for further development of CLS-AX, the outcome of its new efforts to preserve cash and maximize the remaining value in its platform is uncertain.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Clearside Biomedical Inc (CLSD.O) is -1.84, compared to its 5-year average forward P/E of -11.42. For a more detailed relative valuation and DCF analysis to assess Clearside Biomedical Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-11.42
Current PE
-1.84
Overvalued PE
8.89
Undervalued PE
-31.74
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.30
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.36
Undervalued EV/EBITDA
-0.76
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
108.40
Current PS
52.68
Overvalued PS
224.27
Undervalued PS
-7.46
Financials
Annual
Quarterly
FY2025Q2
YoY :
+446.67%
492.00K
Total Revenue
FY2025Q2
YoY :
-52.99%
-3.57M
Operating Profit
FY2025Q2
YoY :
-40.81%
-4.50M
Net Income after Tax
FY2025Q2
YoY :
-40.00%
-0.06
EPS - Diluted
FY2025Q2
YoY :
-22.51%
-4.73M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
YoY :
+99.20%
-533.65
FCF Margin - %
FY2025Q2
YoY :
-89.17%
-913.62
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
13.8K
USD
Months
0-12
1
36.5K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
13.8K
USD
Months
0-12
1
36.5K
USD
Months
CLSD News & Events
Events Timeline
2025-07-23 (ET)
2025-07-23
07:08:18
Clearside Biomedical announces approval of XIPERE in Canada
2025-07-17 (ET)
2025-07-17
07:10:19
Clearside Biomedical transitions all employees to consulting roles
2025-07-17
07:08:56
Clearside Biomedical to explore strategic alternatives to advance SCS platform
Sign Up For More Events
Sign Up For More Events
News
9.5
08-08NASDAQ.COMClearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
9.0
07-23NewsfilterClearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
5.0
07-18BenzingaDeal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie
Sign Up For More News
People Also Watch
FAQ
What is Clearside Biomedical Inc (CLSD) stock price today?
The current price of CLSD is 0.3675 USD — it has decreased -5.16 % in the last trading day.
What is Clearside Biomedical Inc (CLSD)'s business?
What is the price predicton of CLSD Stock?
What is Clearside Biomedical Inc (CLSD)'s revenue for the last quarter?
What is Clearside Biomedical Inc (CLSD)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Clearside Biomedical Inc (CLSD)'s fundamentals?
How many employees does Clearside Biomedical Inc (CLSD). have?